|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2006-6-27
|
|
pubmed:abstractText |
Aromatase inhibitors (AIs) are a novel hormonal therapy for patients with breast cancer. However, AIs can cause bone loss by blocking estrogen production. This study aims to assess the association between AIs and treatment-related bone loss in a large managed-care population of women with breast cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1526-8209
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
7
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
127-32
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16800971-Aged,
pubmed-meshheading:16800971-Aromatase Inhibitors,
pubmed-meshheading:16800971-Breast Neoplasms,
pubmed-meshheading:16800971-Cohort Studies,
pubmed-meshheading:16800971-Female,
pubmed-meshheading:16800971-Fractures, Bone,
pubmed-meshheading:16800971-Humans,
pubmed-meshheading:16800971-Incidence,
pubmed-meshheading:16800971-Insurance Claim Reporting,
pubmed-meshheading:16800971-Middle Aged,
pubmed-meshheading:16800971-Osteoporosis,
pubmed-meshheading:16800971-Prevalence,
pubmed-meshheading:16800971-Retrospective Studies,
pubmed-meshheading:16800971-Risk Assessment
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors.
|
|
pubmed:affiliation |
Mayo Clinic, Jacksonville, FL, USA
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
